ROHTO PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1899-02-22
- Employees
- 7.2K
- Market Cap
- $5.4B
- Website
- http://www.rohto.co.jp
Clinical Trials
45
Active:2
Completed:34
Trial Phases
3 Phases
Phase 1:7
Phase 2:1
Not Applicable:27
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials
Not Applicable
27 (77.1%)Phase 1
7 (20.0%)Phase 2
1 (2.9%)Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
Not Applicable
Not yet recruiting
- Conditions
- Ischemic Heart Disease
- Interventions
- Biological: Placebo
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT07192211
A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)
Phase 2
Completed
- Conditions
- SARS-CoV-2 Infection( COVID-19 )
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT04888949
- Locations
- 🇯🇵
Osaka University Hospital, Suita, Osaka, Japan
A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy
Phase 1
Completed
- Conditions
- Cerebral PalsyPeriventricular Leukomalacia
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04873752
- Locations
- 🇯🇵
Osaka City University Hospital, Osaka, Japan
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection
Phase 1
Completed
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04522986
- Locations
- 🇯🇵
Osaka University Hospital, Suita, Osaka, Japan
An Follow-Up Study of Liver Cirrhosis
Completed
- Conditions
- Decompensated Liver Cirrhosis
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT03472742
- Locations
- 🇯🇵
Niigata University Medical & Dental Hospital, Niigata, Japan
- Prev
- 1
- 2
- Next
News
No news found